Literature DB >> 22888052

Kidney podocytes as specific targets for cyclo(RGDfC)-modified nanoparticles.

Klaus Pollinger1, Robert Hennig, Miriam Breunig, Joerg Tessmar, Andreas Ohlmann, Ernst R Tamm, Ralph Witzgall, Achim Goepferich.   

Abstract

Renal nanoparticle passage opens the door for targeting new cells like podocytes, which constitute the exterior part of the renal filter. When cyclo(RGDfC)-modified Qdots are tested on isolated primary podocytes for selective binding to the αvβ3 integrin receptor a highly cell- and receptor-specific binding can be observed. In displacement experiments with free cyclo(RGDfC) IC(50) values of 150 nM for αvβ3 integrin over-expressing U87-MG cells and 60 nM for podocytes are measured. Confocal microscopy shows a cellular Qdot uptake into vesicle-like structures. Our ex vivo study gives clear evidence that, after renal filtration, nanoparticles can be targeted to podocyte integrin receptors in the future. This could be a highly promising approach for future therapy and diagnostics of podocyte-associated diseases.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Mesh:

Substances:

Year:  2012        PMID: 22888052     DOI: 10.1002/smll.201200733

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  8 in total

1.  Human anti-α3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis.

Authors:  Nino Kvirkvelia; Malgorzata McMenamin; Vanessa Iris Gutierrez; Besarion Lasareishvili; Michael P Madaio
Journal:  Am J Physiol Renal Physiol       Date:  2015-08-19

Review 2.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

3.  Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.

Authors:  Jonathan Wang; Jacqueline J Masehi-Lano; Eun Ji Chung
Journal:  Biomater Sci       Date:  2017-07-25       Impact factor: 6.843

Review 4.  Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions.

Authors:  Yi Huang; Jonathan Wang; Kairui Jiang; Eun Ji Chung
Journal:  J Control Release       Date:  2021-04-20       Impact factor: 11.467

Review 5.  A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease.

Authors:  Yanhong Ma; Fanghao Cai; Yangyang Li; Jianghua Chen; Fei Han; Weiqiang Lin
Journal:  Bioact Mater       Date:  2020-06-15

6.  Polymer Nanoparticle Engineering for Podocyte Repair: From in Vitro Models to New Nanotherapeutics in Kidney Diseases.

Authors:  Claudio Colombo; Min Li; Shojiro Watanabe; Piergiorgio Messa; Alberto Edefonti; Giovanni Montini; Davide Moscatelli; Maria Pia Rastaldi; Francesco Cellesi
Journal:  ACS Omega       Date:  2017-02-20

Review 7.  The potential of RNA-based therapy for kidney diseases.

Authors:  Tjessa Bondue; Lambertus van den Heuvel; Elena Levtchenko; Roland Brock
Journal:  Pediatr Nephrol       Date:  2022-05-04       Impact factor: 3.651

Review 8.  Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases.

Authors:  J P Jose Merlin; Xiaogang Li
Journal:  Front Genet       Date:  2022-01-05       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.